Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 27

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 27
---
 ​ | ​ |
| Tomer Kariv                   | ​ | ​ |     ​ | ​ | ​ |            ​ | ​ | ​ |                                X* | ​ |
| Julius Knowles                | ​ | ​ |     X | ​ | ​ |            ​ | ​ | ​ |                                 X | ​ |
| Ran Nussbaum                  | ​ | ​ |     ​ | ​ | ​ |            X | ​ | ​ |                                 ​ | ​ |
| Alpna Seth, Ph.D.             | ​ | ​ |     ​ | ​ | ​ |        X*(3) | ​ | ​ |                                 ​ | ​ |
| Total meetings in fiscal 2024 | ​ | ​ |     4 | ​ | ​ |            8 | ​ | ​ |                                 6 | ​ |

* Committee Chairperson † Financial Expert (1) Mr. Bienaimé joined our Board in June 2024 and was appointed to serve as a member of our Nominating and Corporate Governance Committee in June 2024. (2) Dr. Gordon served as the Chair of the Compensation Committee until September 2024, after which he continued to serve as a member of the Compensation Committee. (3) Dr. Seth was appointed to serve as the Chair of the Compensation Committee in September 2024, prior to which she served as a member of the Compensation Committee. Below is a description of each committee of the Board. Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities. The Board has determined that each member of each committee meets the applicable Nasdaq rules and regulations regarding “independence,” and each member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to the Company. Audit Committee The Audit Committee is currently composed of three directors: Dr. Gray (Chair), Mr. Farzan and Mr. Knowles. The Audit Committee met four times during 2024. The Audit Committee also acts periodically by unanimous written consent in lieu of a formal meeting. The Board has adopted a written Audit Committee charter that is available to stockholders on our website at ir.kerostx.com . The Board reviews the Nasdaq listing standards definition of independence for Audit Committee members on an annual basis and has determined that all of the current members of the Audit Committee are independent (as independence is currently defined under Rule 5605(c)(2)(A)(i) and (ii) of the Nasdaq